Avaxia will primarily use the proceeds to advance the clinical development of its lead program, AVX-470, for the treatment of inflammatory bowel disease (IBD).

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

128 Spring St. 620
Lexington, MA 02421
USA

Phone

(781) 861-0062

Website

www.avaxiabiologics.com

Email Address

[email protected]

Overview

Avaxia Biologics develops orally-delivered antibody therapeutics using a proprietary antibody platform.

Profile

Social Media

Avaxia Biologics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Barbara Fox

Chief Financial Officer

David Neafus

VP - Operations

Neil Schauer

Browse more venture capital transactions:

Prev: 6/7/2013: SkyFuel venture capital transaction
Next: 6/7/2013: Healthation venture capital transaction

Share this article

About Our VC Transactions Data

We record every notable VC transaction. All VC database entries on this site are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary